Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

DCRN
8847
not without risk, and is associated with higher frequencies of gastrointestinal bleeding and hemorrhagic
stroke. Identification of patients most likely to benefit from antiplatelet therapy with aspirin or other
agents may be useful. Measurement of urinary 11-dTXB2 concentration may be used to assess an
individual's platelet activity and associated risk for developing cardiovascular events, as well as identify
individuals most likely to benefit from antiplatelet therapy. Urinary 11-dTXB2 offers an advantage over
platelet-activation markers measured in plasma or blood because it is not subject to interference from in
vitro platelet activation, which can easily occur as a result of local vein trauma or insufficient
anticoagulation during blood sample collection.
Useful For: Determining increased risk of coronary heart disease and stroke Identifying patients most
likely to benefit from antiplatelet therapy
Interpretation: Elevated baseline levels of 11-dehydro-thromboxane B2 (11-dTXB2) in patients may
indicate an increase in platelet activation and thrombosis resulting from atherosclerotic deposits or other
vascular obstructions. Patients that exhibit 11-dTXB2 values above the normal reference value may be at
increased risk for an ischemic cardiovascular event. Elevations of 11-dTXB2 in patients already receiving
anti-platelet therapy suggest a continued hypercoagulable state and alternative anti-thrombotic or
anti-platelet therapies should be considered.
Reference Values:
Males > or =18 years: 0-1,089 pg/mg of creatinine
Females > or =18 years: 0-1,811 pg/mg of creatinine
Reference values have not been established for patients that are 90% of
cases), with the third most common form of CAH (3-beta-steroid dehydrogenase deficiency,